<DOC>
	<DOCNO>NCT00001046</DOCNO>
	<brief_summary>PRIMARY : To evaluate short-term safety rgp120/HIV-1SF2 vaccine versus MF59 placebo administer HIV-infected pregnant woman . SECONDARY : To evaluate immunogenicity long-term safety rgp120/HIV-1SF2 HIV-infected pregnant woman receive vaccine pregnancy pregnancy postpartum . To evaluate immunogenicity safety infant 18 month age follow maternal immunization vaccine pregnancy . Active immunization HIV-infected woman pregnancy may slow progression maternal disease , reduce titer virus maternal plasma , increase titer epitope-specific antibody . Also , active immunization potential induce primary immunity fetus boost T-cell humoral immune response HIV mother .</brief_summary>
	<brief_title>Active Immunization HIV-Infected Pregnant Women : A Phase I Study Safety Immunogenicity rgp120/HIV-1 Vaccine ( NOTE : Some Patients Receive Placebo )</brief_title>
	<detailed_description>Active immunization HIV-infected woman pregnancy may slow progression maternal disease , reduce titer virus maternal plasma , increase titer epitope-specific antibody . Also , active immunization potential induce primary immunity fetus boost T-cell humoral immune response HIV mother . Women randomize receive rgp120/HIV-1SF2 vaccine MF59 placebo . Patients receive first immunization 16 24 week gestation monthly thereafter delivery , maximum five immunization . Patients may continue receive immunization regimen originally assign 3 , 6 , 9 , 12 month postpartum . Maternal follow-up continue 18 month postpartum ; infant follow age 18 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed pregnancy : AZT . Methadone maintenance . NOTE : Patients may initiate antiretroviral therapy disease progression . NOTE : Patients may change AZT another antiretroviral agent may begin antiretroviral therapy follow delivery , clinically indicate . Patients must : Documented HIV infection . CD4 count &gt; = 400 cells/mm3 ( average two determination obtain 1 week apart ) . No clinical criterion diagnosis AIDS . HIV p24 antigen &lt; = 30 pg/ml . Estimated gestational age 16 24 week , confirm baseline sonogram demonstrate congenital abnormality consider incompatible life . Intention carry pregnancy term . Willingness follow ACTU duration study . NOTE : Father fetus ( available reasonable attempt contact ) must provide informed consent . Prior Medication : Allowed : AZT . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity component vaccine . Hepatitis B antigen positive study entry . Evidence lifethreatening serious preexist fetal abnormality ( e.g. , anencephaly , renal agenesis , Potter 's syndrome ) . Evidence syphilis require therapy pregnancy . Intention breastfeed . Presence obstetrical highrisk factor : insulindependent diabetes hypertension require use antihypertensive therapy repeat intrauterine fetal demise Rhsensitization blood group alloimmunization diseases require use immunosuppressive therapy ( e.g. , asthma , lupus ) . Concurrent Medication : Excluded pregnancy : Antiretrovirals AZT . Immunomodulating agent ( e.g. , HIVIG , IVIG ) . Other investigational drug immunosuppressive agent . NOTE : Patients may change AZT another antiretroviral agent may begin antiretroviral therapy follow delivery , clinically indicate . Prior Medication : Excluded within 90 day prior study entry : Antiretrovirals AZT . Immunomodulating agent ( e.g. , HIVIG , IVIG ) . Current use illicit drug chronic alcohol use patient history .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>